Abstract:Radiation-induced foci (RIF) are nuclear puncta visualized by immunostaining of proteins that regulate DNA double-strand break (DSB) repair after exposure to ionizing radiation. RIF are a standard metric for measuring DSB formation and repair in clinical, environmental and space radiobiology. The time course and dose dependence of their formation has great potential to predict in vivo responses to ionizing radiation, predisposition to cancer and probability of adverse reactions to radiotherapy. However, increa… Show more
“…While the high dose rate used in EBRT intends to overwhelm the DNA repair capacity, the low dose rate applied with 177 Lu-DOTATATE in a protracted exposure gives cells sufficient time to repair a fraction of damage before the creation of subsequent breaks. Consequently, DNA DSB formation is competing with DNA damage repair in this time window [ 23 ], resulting in a challenging distinction from background variability. Additional differences related to distribution pattern as well as size of foci, representing DNA damage complexity, might be expected between 177 Lu-DOTATATE and EBRT and could be addressed by looking at individual cells by radiation-induced foci detection by microscopy.…”
Section: Discussionmentioning
confidence: 99%
“…Nevertheless, flow cytometry analysis allowed us to semi-quantitatively assess a large number of conditions (cell lines and time points) to have a first general idea on the extent and kinetics differences between 177 Lu-DOTATATE and EBRT in a panel of cancer cell lines. In EBRT-treated cells, elevated γH2AX/pATM levels observed from 72 h post irradiation might represent a combination of residual unrepaired DSBs, but also apoptotic cells which have also been associated with high γH2AX expression [ 23 , 24 ]. Indeed, apoptosis was observed to be already induced at day 3 in our cell lines, namely COLO-677, EJM and MIA-PACA-2 after EBRT.…”
Radionuclide Therapy (RNT) with 177Lu-DOTATATE targeting somatostatin receptors (SSTRs) in neuroendocrine tumours (NET) has been successfully used in routine clinical practice, mainly leading to stable disease. Radiobiology holds promise for RNT improvement but is often extrapolated from external beam radiation therapy (EBRT) studies despite differences in these two radiation-based treatment modalities. In a panel of six human cancer cell lines expressing SSTRs, common radiobiological endpoints (i.e., cell survival, cell cycle, cell death, oxidative stress and DNA damage) were evaluated over time in 177Lu-DOTATATE- and EBRT-treated cells, as well as the radiosensitizing potential of poly (ADP-ribose) polymerase inhibition (PARPi). Our study showed that common radiobiological mechanisms were induced by both 177Lu-DOTATATE and EBRT, but to a different extent and/or with variable kinetics, including in the DNA damage response. A higher radiosensitizing potential of PARPi was observed for EBRT compared to 177Lu-DOTATATE. Our data reinforce the need for dedicated RNT radiobiology studies, in order to derive its maximum therapeutic benefit.
“…While the high dose rate used in EBRT intends to overwhelm the DNA repair capacity, the low dose rate applied with 177 Lu-DOTATATE in a protracted exposure gives cells sufficient time to repair a fraction of damage before the creation of subsequent breaks. Consequently, DNA DSB formation is competing with DNA damage repair in this time window [ 23 ], resulting in a challenging distinction from background variability. Additional differences related to distribution pattern as well as size of foci, representing DNA damage complexity, might be expected between 177 Lu-DOTATATE and EBRT and could be addressed by looking at individual cells by radiation-induced foci detection by microscopy.…”
Section: Discussionmentioning
confidence: 99%
“…Nevertheless, flow cytometry analysis allowed us to semi-quantitatively assess a large number of conditions (cell lines and time points) to have a first general idea on the extent and kinetics differences between 177 Lu-DOTATATE and EBRT in a panel of cancer cell lines. In EBRT-treated cells, elevated γH2AX/pATM levels observed from 72 h post irradiation might represent a combination of residual unrepaired DSBs, but also apoptotic cells which have also been associated with high γH2AX expression [ 23 , 24 ]. Indeed, apoptosis was observed to be already induced at day 3 in our cell lines, namely COLO-677, EJM and MIA-PACA-2 after EBRT.…”
Radionuclide Therapy (RNT) with 177Lu-DOTATATE targeting somatostatin receptors (SSTRs) in neuroendocrine tumours (NET) has been successfully used in routine clinical practice, mainly leading to stable disease. Radiobiology holds promise for RNT improvement but is often extrapolated from external beam radiation therapy (EBRT) studies despite differences in these two radiation-based treatment modalities. In a panel of six human cancer cell lines expressing SSTRs, common radiobiological endpoints (i.e., cell survival, cell cycle, cell death, oxidative stress and DNA damage) were evaluated over time in 177Lu-DOTATATE- and EBRT-treated cells, as well as the radiosensitizing potential of poly (ADP-ribose) polymerase inhibition (PARPi). Our study showed that common radiobiological mechanisms were induced by both 177Lu-DOTATATE and EBRT, but to a different extent and/or with variable kinetics, including in the DNA damage response. A higher radiosensitizing potential of PARPi was observed for EBRT compared to 177Lu-DOTATATE. Our data reinforce the need for dedicated RNT radiobiology studies, in order to derive its maximum therapeutic benefit.
“…The other important future direction is to address why OPCs are not able to support RAD51 filament formation to the same extent as NSPCs, especially given that RPA filament formation levels are comparable, as are transcription of the RAD51, RAD52, BRCA1 and BRCA2 genes (Figure 6F ) that are RAD51-associated factors important for RAD51 function in DSB repair ( 93 , 94 ). To consolidate this work, it will be important to systematically monitor the mRNA and protein expression of all RAD51-regulatory factors in both the in vitro cell models used here, as well as in vivo mouse brains across early development.…”
Cranial irradiation is part of the standard of care for treating pediatric brain tumors. However, ionizing radiation can trigger serious long-term neurologic sequelae, including oligodendrocyte and brain white matter loss enabling neurocognitive decline in children surviving brain cancer. Oxidative stress-mediated oligodendrocyte precursor cell (OPC) radiosensitivity has been proposed as a possible explanation for this. Here, however, we demonstrate that antioxidants fail to improve OPC viability after irradiation, despite suppressing oxidative stress, suggesting an alternative etiology for OPC radiosensitivity. Using systematic approaches, we find that OPCs have higher irradiation-induced and endogenous γH2AX foci compared to neural stem cells, neurons, astrocytes and mature oligodendrocytes, and these correlate with replication-associated DNA double strand breakage. Furthermore, OPCs are reliant upon ATR kinase and Mre11 nuclease-dependent processes for viability, are more sensitive to drugs increasing replication fork collapse, and display synthetic lethality with PARP inhibitors after irradiation. This suggests an insufficiency for homology-mediated DNA repair in OPCs—a model that is supported by evidence of normal RPA but reduced RAD51 filament formation at resected lesions in irradiated OPCs. We therefore propose a DNA repair-centric mechanism of OPC radiosensitivity, involving chronically-elevated replication stress combined with ‘bottlenecks’ in RAD51-dependent DNA repair that together reduce radiation resilience.
“…DNA damage, especially DSB, rapidly induces the DNA damage response (DDR) pathway [ 133 , 142 ]. The primary pathways of DBS DNA repair are homologous recombination repair (HRR), non-homologous end-joining (NHEJ), and alternative end-joining (alt-EJ) [ 133 , 142 , 143 , 144 ]. These three pathways involve different initiating proteins that recognize DSB and different downstream enzymes ( Table 4 ).…”
Section: Signal Transduction By High and Low Letmentioning
Exposure to ionizing radiation can occur during medical treatments, from naturally occurring sources in the environment, or as the result of a nuclear accident or thermonuclear war. The severity of cellular damage from ionizing radiation exposure is dependent upon a number of factors including the absorbed radiation dose of the exposure (energy absorbed per unit mass of the exposure), dose rate, area and volume of tissue exposed, type of radiation (e.g., X-rays, high-energy gamma rays, protons, or neutrons) and linear energy transfer. While the dose, the dose rate, and dose distribution in tissue are aspects of a radiation exposure that can be varied experimentally or in medical treatments, the LET and eV are inherent characteristics of the type of radiation. High-LET radiation deposits a higher concentration of energy in a shorter distance when traversing tissue compared with low-LET radiation. The different biological effects of high and low LET with similar energies have been documented in vivo in animal models and in cultured cells. High-LET results in intense macromolecular damage and more cell death. Findings indicate that while both low- and high-LET radiation activate non-homologous end-joining DNA repair activity, efficient repair of high-LET radiation requires the homologous recombination repair pathway. Low- and high-LET radiation activate p53 transcription factor activity in most cells, but high LET activates NF-kB transcription factor at lower radiation doses than low-LET radiation. Here we review the development, uses, and current understanding of the cellular effects of low- and high-LET radiation exposure.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.